(July.27th-31th)

30. Daiichi Sankyo announced on July 27 that it entered into a global cooperation and development agreement with AstraZeneca for Daiichi Sankyo’s DS-1062, a TROP2-targeted ADC currently in phase 1 clinical development for NSCLC and TNBC, with the total amount involved in the collaboration of up to USD6 billion.

31. Terns Pharmaceuticals and Hansoh Pharmaceutical entered into a collaboration agreement for TRN-000632 on July 29, according to which, Hansoh will receive the exclusive rights to develop and commercialize TRN-000632 in Greater China, and the total amount of this transaction reaches USD68 million. TRN-000632 is a potent allosteric inhibitor of BCR-ABL.

Read More:

Pharmaceutical News of the Week | CPhI.CN - Approval

About  the Author:    

Caicai, a Master of Pharmacy from Shanghai Jiaotong University, used to work in the Institute of Science and Technical Information. Currently as a practitioner in the drug surveillance system, she is good at interpreting industry regulations, pharmaceutical research developments, etc.

-----------------------------------------------------------------------
Editor's Note:

To become a freelance writer of PharmaSources.com,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@imsinoexpo.com.